Theresa A. Guise, MD FASBMR, Abell-Hanger Foundation Distinguished Professor, Section Chief, Bone and Mineral Disorders, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center Scholar, Cancer Prevention Research Institute of Texas, Co-Leader, The Lawrence Family Bone Disease Program of Texas
Theresa is one of the most distinguished and acknowledged scientific bone metastasis experts with a long career in bone metastasis research, and she conducts clinical practice treating patients with bone metastases. Her research group made the groundbreaking discovery of the vicious cycle of bone metastases, where tumor cells in bone promote bone resorption by osteoclasts, and the increased bone resorption further promotes the growth of tumor cells in bone, with key roles of tumor-produced PTHrP and bone-derived TGFβ.
Paul Kostenuik, PhD Founder and owner, Phylon Pharma Services, Thousand Oaks, CA
Dr. Kostenuik’s PhD thesis was on mechanisms of bone metastasis, a focus that continued as lead scientist on Amgen’s denosumab program. Paul supported the molecule throughout its preclinical and clinical development programs, regulatory approval, and blockbuster commercial status. Denosumab (Prolia®) was approved by the FDA in 2009 for osteoporosis, and denosumab (Xgeva®) was approved in November 2010 for the prevention of skeletal-related events such as fractures in patients with bone metastases from solid tumors.
Read more in: http://www.phylonps.com/biography.html